Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Alnylam: ATTR Franchise Takes the Lead, What’s the Growth Trajectory, Competitive Risk & Valuation Reset?
Alnylam’s Q1 2025 results reflect a high-quality inflection point across both commercial execution and pipeline durability, with $469M in total product revenue (+28% y/y) led by 45% growth in the TTR franchise and a strong showing from AMVUTTRA. U.S. growth remains robust in hATTR-PN, while early traction in the newly approved ATTR-CM indication is promising, with formulary access achieved across >50% of top health systems within four weeks post-approval. HELIOS-B data, showing a 36% reduction in all-cause mortality and favorable functional and safety outcomes, is supporting uptake across prescriber and patient types, reinforcing AMVUTTRA’s differentiated RNAi profile. Operating leverage was evident, with $75M in non-GAAP operating income and stable 85% gross margins ahead of anticipated H2 royalty step-ups. Rare disease assets GIVLAARI and OXLUMO posted modest growth, while the pipeline showed breadth, with TRITON-CM for Nucresiran, EU/Japan regulatory progress, and early-stage programs in diabetes and hematology broadening long-term optionality. Guidance reaffirmation implies a strong CM ramp and steady execution. With $2.6B in cash and a clear visibility to platform scalability, Alnylam appears well-capitalized to navigate an increasingly competitive RNAi space. Can AMVUTTRA sustain its first-mover momentum in ATTR-CM and outpace new entrants while preserving margin discipline and pipeline leadership?
